About this event
- Date and time Fri 14 Nov 2025 from 9:30am to 4:45pm
- Location Royal Society of Medicine
- Organised by Oncology, Ophthalmology
Join us for a joint meeting with RSM's Oncology and Ophthalmology section dedicated to cancer therapy-related eye toxicities—bringing together oncology, ophthalmology, and optometry to shape the future of patient care.
With the introduction of Antibody-Drug Conjugates (ADCs) and other next-generation cancer therapies, many patients are experiencing improved survival, but a new challenge is emerging: ocular toxicities. These side effects can seriously impact vision, disrupt treatment schedules, and reduce the quality of life. However, early recognition and expert management can allow cancer treatment to continue, protect vision, and optimise survivorship.
Despite these needs, current management pathways for ocular toxicity remain fragmented and inconsistent across the NHS. There is an urgent and growing need for streamlined, national strategies to identify, monitor, and manage eye toxicities, as well as to support professionals dealing with this complexity for the first time.
Why attend?
- Join oncologists, oncology nurse practitioners, ophthalmologists, optometrists, pharmacists, and other key stakeholders to address this urgent unmet clinical need - together for the first time.
- Hear from national experts on the mechanisms, diagnosis, and management of ADC- and other therapy-related eye complications.
- Participate in workshops, real-world case reviews, and multidisciplinary panel discussions to build confidence in handling these complex side effects.
- Play an active role in co-developing practical, multidisciplinary pathways that will inform care standards and improve outcomes for cancer patients across the NHS.
Event highlights
- Recognise the key eye complications associated with cancer therapies, especially with ADCs.
- Identify optimal referral strategies and management approaches for ocular toxicities - know when, how, and to whom to refer.
- Learn about up-to-date imaging and diagnostic techniques for monitoring patients at risk.
- Collaborate with your peers in a practical session dedicated to co-creating actionable multidisciplinary pathways for NHS-wide adoption.
Who should attend?
- Oncologists and oncology nurse practitioners
- Ophthalmologists
- Optometrists
- Oncology pharmacists
- Anyone involved in the management or referral of cancer patients with potential or emerging ocular toxicities
Register now and take an active role in shaping national standards for cancer therapy-related ocular toxicity management.
Follow us on:
Facebook
Instagram
LinkedIn
Twitter
YouTube
We would like to thank sponsors AbbVie, Genmab and GSK for their financial support of this meeting. Our sponsors have had no influence or input into the agenda, content, speaker selection or materials of the event.
Agenda
View the programme
Registration, tea and coffee
Welcome and introduction
Professor Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, President of RSM Oncology Section, and Miss Evelyn Mensah, Consultant Ophthalmologist, London North West University Healthcare NHS Trust, President of RSM Ophthalmology Section
Session 1: The cancer drugs
Chair: Professor Susana Banerjee
Antibody Drug Conjugates (ADCs) - transforming cancer treatment
Professor Susana Banerjee
Ocular Toxicities - new toxicities in oncology: The oncology/haematology perspective
Professor Susana Banerjee
Panel discussion
Tea and coffee break
Session 2: The patient
Chair: Michael Bowen, Director of Knowledge & Research at The College of Optometrists
Mechanisms of cancer-drug related ocular toxicities and management implications
Professor Sajjad Ahmad, Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust
How to identify and monitor ocular toxicities?
Mr Luke Michaels, Consultant Ophthalmologist, Guy’s and St Thomas’ NHS Foundation Trust
Panel discussion
Lunch
Session 3: The pathway
Chair: Evelyn Mensah
Facilitators: Hinal Kumar, Ivie Itua, Jackie Odunwo, Arya Ghatge, Sarah Bird
Optimising patient ocular toxicity pathways - workshop and group discussion
Panel discussion
- Group discussion with feedback and consolidation
Tea and coffee break
Session 4: The collaboration
Chairs: Professor Sajjad Ahmad and Dr Rowan Miller
Challenges developing patient pathways for ocular toxicities: Examples from Belantamab mafodotin in multiple myeloma
Dr Kevin Boyd, Consultant Haematologist, The Royal Marsden NHS Foundation Trust
Lessons to learn – optometry, ophthalmology, community integration
Irfan Razvi, Council member (West Midlands) the College of Optometrists, Chair Staffordshire Local Optical Committee, Specialist Optometrist and Director
Pemigatinib & the pathway to ophthalmic imaging
Arya Ghatge, Ophthalmology Research Fellow, Gloucestershire Hospitals NHS Foundation Trust
Cancer treatment-related ocular toxicities- what research is needed to improve outcomes?
Dr Rowan Miller, Consultant Medical Oncologist, University College London
Panel discussion
Next steps
Susana Banerjee and Evelyn Mensah
Close of Meeting
Sponsors
Location
Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom
Registration for this event will close at 1:00am on 13 November 2025. Late registrations will not be accepted.
The agenda is subject to change at any time.
If the event is recorded, we are only able to share presentations that we have received permission to share. There is no guarantee that all sessions will be available after the event, this is at the presenter’s and RSM’s discretion.
All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations.
This event will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.